Tonix Pharmaceuticals Presents Phase 1 Formulation Development Data for TNX-601 CR in a Poster Presentation at CNS Summit 2021GlobeNewsWire • 11/09/21
Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the American College of Rheumatology Convergence 2021GlobeNewsWire • 11/08/21
Tonix Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational HighlightsGlobeNewsWire • 11/08/21
Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Infectious Disease R&D Center in MarylandGlobeNewsWire • 10/15/21
Tonix Pharmaceuticals Announces Completion of Acquisition of Infectious Disease R&D Center in Frederick, MarylandGlobeNewsWire • 10/04/21
Tonix Pharmaceuticals Expands Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and TherapeuticsGlobeNewsWire • 09/23/21
Tonix Pharmaceuticals to Present at the Cantor Virtual Global Healthcare ConferenceGlobeNewsWire • 09/22/21
Why Shares of GameStop, Naked Brand Group, and Tonix Pharmaceuticals Were Soaring TodayThe Motley Fool • 08/24/21
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)GlobeNewsWire • 08/24/21
Tonix Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational HighlightsGlobeNewsWire • 08/09/21
Tonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine ProgramsGlobeNewsWire • 08/02/21
Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral DrugsGlobeNewsWire • 07/27/21